

Claims

1. Use of 5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl (benzoxymethyl)] phosphate (NUC-3373), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a patient, wherein the medicament is to be administered over a period of between 1 and 6 hours.
2. The use according to claim 1, wherein the medicament is to be administered by means of infusion.
3. The use according to any of the preceding claims, wherein the medicament is to be administered by means of or includes a bolus administration.
4. The use according to any preceding claim, wherein the patient with the cancer also suffers from hand-foot syndrome.
5. The use according to claim 4, wherein the patient has developed hand-foot syndrome from a previous treatment regimen with a drug other than NUC-3373.
6. The use according to claim 5, wherein the patient has developed hand-foot syndrome when being treated with 5FU, capecitabine or tegafur.
7. Use of 5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl (benzoxymethyl)] phosphate (NUC-3373) or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in a subject that is at risk of developing or suffers from hand-foot syndrome, optionally wherein the subject has developed hand-foot syndrome following treatment with a fluoropyrimidine such as 5FU, capecitabine or tegafur.
8. The use according to any preceding claim, wherein the cancer is selected from the group consisting of: pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, other urothelial cancers, gastrointestinal cancer (also known as cancer of the digestive tract), liver cancer, lung cancer, biliary cancer, prostate cancer, cholangiocarcinoma, renal cancer, neuroendocrine cancer, sarcoma, lymphoma, leukemia, cervical cancer, thymic cancer, a cancer of an unknown primary origin, mesothelioma, adrenal cancer, cancer of the uterus, cancer of the fallopian tube, peritoneal cancer, endometrial cancer, testicular cancer, head and neck cancer, the central nervous system cancer, basal cell carcinoma, Bowens disease, other skin cancers (such as malignant melanoma, merckel cell tumour and rare appendage tumours), ocular surface squamous neoplasia and germ cell tumours.
9. The use according to claim 8, wherein the cancer is gastrointestinal cancer and is selected from the group consisting of: oesophageal cancer, gastric cancer, stomach cancer,

bowel cancer, small intestine cancer, colon cancer, appendix mucinous, goblet cell carcinoid, liver cancer, biliary cancer, gallbladder cancer, anal cancer and rectal cancer.

10. Use of 5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl (benzoxy-L-alaninyl)] phosphate (NUC-3373), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of cancer in subjects that are deficient or partially deficient in dihydropyrimidine dehydrogenase (DPD).

11. The use according to claim 10, wherein the cancer is selected from the group consisting of: pancreatic cancer, breast cancer, ovarian cancer, bladder cancer, other urothelial cancers, gastrointestinal cancer (also known as cancer of the digestive tract), liver cancer, lung cancer, biliary cancer, prostate cancer, cholangiocarcinoma, renal cancer, neuroendocrine cancer, sarcoma, lymphoma, leukemia, cervical cancer, thymic cancer, a cancer of an unknown primary origin, mesothelioma, adrenal cancer, cancer of the uterus, cancer of the fallopian tube, peritoneal cancer, endometrial cancer, testicular cancer, head and neck cancer, the central nervous system cancer, basal cell carcinoma, Bowens disease, other skin cancers (such as malignant melanoma, merckel cell tumour and rare appendage tumours), ocular surface squamous neoplasia and germ cell tumours.

12. The use according to claim 10 or 11, wherein the cancer is gastrointestinal cancer and is selected from the group consisting of: oesophageal cancer, gastric cancer, stomach cancer, bowel cancer, small intestine cancer, colon cancer, appendix mucinous, goblet cell carcinoid, liver cancer, biliary cancer, gallbladder cancer, anal cancer and rectal cancer.

13. The use according to any one of claims 10 to 12, wherein the subject has a genetic mutation selected from IVS14+1G>A mutation in intron 14 coupled with exon 14 deletion (known as DPYD*2A), 496A>G in exon 6; 2846A>T in exon 22; and T1679G (DPYD*13) in exon 13.

14. The use according to any one of claims 10 to 12, wherein the subject has previously exhibited intolerance for 5FU or capecitabine or has a family history of intolerance for 5FU or capecitabine.